Validation of NG2 antigen in identifying BP-ALL patients with MLL rearrangements using qualitative and quantitative flow cytometry: a prospective study.
Zangrando
A
A
Intini
F
F
te Kronnie
G
G
Basso
G
G
D000941:Antigens / Q000032:analysis*; D002675:Child, Preschool; D015331:Cohort Studies; D005434:Flow Cytometry; D015321:Gene Rearrangement; D011495:Histone-Lysine N-Methyltransferase; D006801:Humans; D051788:Myeloid-Lymphoid Leukemia Protein / Q000235:genetics*; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis* / Q000235:genetics; D011446:Prospective Studies; D011509:Proteoglycans / Q000032:analysis*; D000099216:Chondroitin Sulfate Proteoglycan 4
D000941:Antigens; D011495:Histone-Lysine N-Methyltransferase; D051788:Myeloid-Lymphoid Leukemia Protein; D011509:Proteoglycans; D000099216:Chondroitin Sulfate Proteoglycan 4; C497422:KMT2A protein, human